CoChat
Sign Up
Cited by 175Treatment of Major DepressionPsychotherapy Techniques and ApplicationsAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index.

The Treatment for Adolescents With Depression Study (TADS)

Open access
MARCH, JOHN, SILVA, SUSAN, VITIELLO, BENEDETTO·2006·Journal of the American Academy of Child & Adolescent Psychiatry
DOI 10.1097/01.chi.0000237709.35637.c0
Open this paper in CoChat — free accountOpen PDF

Abstract

Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is intended to evaluate the short-term (12 weeks) and longer-term (36 weeks) effectiveness of four treatments for adolescents with DSM-IV major depressive disorder: clinical management with fluoxetine (FLX), cognitive-behavioral therapy (CBT), FLX and CBT combined (COMB), and clinical management with placebo (PBO). We previously reported that COMB and FLX were more effective in reducing depression than CBT or PBO after 12 weeks of acute treatment. In this special section of the Journal, separate articles extend these findings to the impact of TADS treatments on remission, speed of response, function and quality of life, predictors of outcome, and safety during the first 12 weeks of treatment. To set the stage for the special section, we briefly review the rationale, design, and methods of the TADS; describe the TADS sample to which the TADS findings generalize; using all of the currently available data, summarize the intent-to-treat outcomes across multiple endpoints at 12 weeks; and consider the public health value of the TADS findings in the context of design decisions and methodological limitations of the TADS, including some that may have advantaged the combined treatment condition. Reflecting the ordering of effect sizes at week 12--COMB (0.98) > FLX (0.68) > CBT (-0.03)--combined treatment proved superior to PBO on 15 of 16 endpoints, to CBT on 14 of 16 endpoints, and to FLX on 8 of 16 endpoints, whereas FLX was superior to CBT on 8 of 14 and to PBO on 7 of 16 measures. CBT did not differ from PBO on any measure. Despite the fact that suicidality improved markedly across all of the treatment conditions, suicidal events were twice as common in patients treated with FLX alone than with COMB or CBT alone, perhaps indicating that CBT protects against suicidal events. Thus, combined treatment appears to accelerate recovery relative to CBT and, for some outcomes, FLX alone, while minimizing the risk of suicidality relative to FLX alone. Taking benefit and risk into account, we conclude that the combination of FLX and CBT appears superior to either monotherapy as a treatment for moderate to severe major depressive disorder in adolescents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.chi.0000237709.35637.c0

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 175

Related

See all

Metadata

Authors
MARCH, J., SILVA, S., & VITIELLO, B.
Affiliations
  • Duke University (US)
  • Pfizer (United States) (US)
  • Suburban Hospital (US)
Corresponding author
MARCH, JOHN
ORCID
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2006-12
Volume
45
Issue
12
Pages
1393-1403
ISSN
0890-8567 (ISSN-L)
DOI
10.1097/01.chi.0000237709.35637.c0
OpenAlex
W171724531
Cited by
174
References
81
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 10 · 2015: 5 · 2014: 9 · 2013: 8 · 2012: 17
FWCI
13.57
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • U.S. Department of Health and Human Services
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Kaiser Permanente
  • Northwestern University
  • Johns Hopkins University
  • University of Pittsburgh
  • University of Cincinnati
  • Case Western Reserve University
  • University of Oregon
  • York University
  • National Institutes of Health (n01mh080008-004, 98DS-0008)
  • National Institute of Mental Health (N01 MH 80008, 98-DS-0008, RFP-NIH-NIMH 98-DS-0008)
  • Duke Clinical Research Institute
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
adolescent depression, major depressive disorder, fluoxetine, cognitive behavioral therapy, combined psychotherapy and pharmacotherapy, treatment efficacy, remission, response speed, quality of life, suicidality, treatment safety, prognostic factors, placebo response
MeSH terms
Adolescent, Combined Modality Therapy, Major Depressive Disorder, Fluoxetine, Humans, Quality of Life, Remission Induction, Severity of Illness Index, Cognitive Behavioral Therapy, Selective Serotonin Reuptake Inhibitors, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review